News

January 18, 2023

National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma’s neflamapimod in dementia with Lewy bodies

BOSTON, MA, January 18th, 2022 /PRNewswire/ – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in […]

Read More

December 2, 2022

Presentation of MRI data at Clinical Trials and Alzheimer’s Disease (CTAD) conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer’s disease (AD)

In structural MRI images obtained before and after 12 weeks treatment, neflamapimod significantly increased the volume of the Nucleus Basalis of Meynert, the major nucleus of cholinergic neurons in the basal forebrain, in patients with early AD BOSTON, MA, December 2nd, 2022 /PRNewswire/ – EIP Pharma Inc., a private clinical stage biopharmaceutical company focused on […]

Read More

September 21, 2022

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

  EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications – Neflamapimod demonstrates that it reverses the neurodegenerative process in the basal forebrain cholinergic system in animal models – – Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on […]

Read More

View All News



Presentations




View All Presentations

About EIP

Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.

Contact Us